Gantenerumab Continues to Show Promise in Reduction of Amyloid Plaques

Gantenerumab Continues to Show Promise in Reduction of Amyloid Plaques
Latest findings from the open-label extension (OLE) Phase 3 clinical trials Scarlet RoAD (NCT01224106) and Marguerite RoAD (NCT02051608) on gantenerumab (RG1450, RO4909832) continue to show significant reductions in the accumulation of amyloid plaques in patients with Alzheimer's disease with and without amyloid-related imaging abnormalities-edema (ARIA-E). The findings were presented during the AD/PD 2019 14th​ International Conference on Alzheimer's and Parkinson's Diseases, held March 26–31 in Lisbon, Portugal. Alzheimer's disease is a progressive neurodegenerative disorder characterized by the formation of plaques made of a protein called beta-amyloid that accumulate between nerve cells in the brain, disrupting their function. Gantenerumab is an investigational fully human antibody that has been designed to bind to beta-amyloid and prevent the formation and accumulation of plaques between brain cells. The therapy had initially been developed by Chugai Pharmaceutical, but is now part of a collaboration between
Subscribe or to access all post and page content.